HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study.

Abstract
A dose-ranging, baseline-controlled study was undertaken to assess the safety and effectiveness of a 24-hour infusion of etidronate disodium in treating patients with hypercalcemia of malignant disease. Patients with hypercalcemia refractory to at least 48 h of saline loading (greater than 3 1/day) with two albumin-adjusted serum calcium values between 11.1 and 12.0 mg/dl or one albumin-adjusted serum calcium greater than 12.0 mg/dl within 48 h of therapy were admitted to the study. A total of 26 patients were treated in a dose-escalating fashion with 5, 10, 15, 20 or 25 mg/kg of intravenous etidronate disodium over 24 h. Patients treated with 5, 10 or 15 mg/kg did not have significant reductions in albumin-adjusted serum calcium during the first 7 days. In the 6 patients who made up the 20 mg/kg group, adjusted serum calcium levels fell from an average of 13.8 +/- 0.5 mg/dl on day 1 before infusion to 11.7 +/- 0.3 mg/dl (p less than 0.05) by day 7. In the 8 patients in the 25 mg/kg group, adjusted serum calcium levels decreased from an average of 12.9 +/- 0.5 mg/dl on day 1 before infusion to 10.9 +/- 0.4 mg/dl (p less than 0.05) by day 7. All 8 patients in the 25 mg/kg group achieved a fall in albumin-adjusted serum calcium to less than 11.1 mg/dl within the 1 week with a minimum decrement of 0.6 mg/dl and a maximum of 5.5 mg/dl.(ABSTRACT TRUNCATED AT 250 WORDS)
AuthorsJ F Flores, F R Singer, R K Rude
JournalMineral and electrolyte metabolism (Miner Electrolyte Metab) Vol. 17 Issue 6 Pg. 390-5 ( 1991) ISSN: 0378-0392 [Print] Switzerland
PMID1823390 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Etidronic Acid
Topics
  • Etidronic Acid (administration & dosage, adverse effects)
  • Humans
  • Hypercalcemia (drug therapy, etiology)
  • Infusions, Intravenous
  • Neoplasms (complications)
  • Pilot Projects
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: